Seoul National University

Ticaros Co., Ltd.

Hyung-Bae Park

Ki-Hyun Kim

Soohyun Kim

Junho Chung

Ji Eun Lee

Eun-Young Choi

Hyori Kim

Giri Nam

Ji-Eun Lee

Hye-Ran Yeon

Kyungho Choi

Yumi Oh

The present invention relates to a novel chimeric antigen receptor comprising a CD99 region which participates in immune synapse stabilization as a backbone of the chimeric antigen receptor, an immune cell comprising the same, and the uses thereof. CD99-based CAR-T cells are capable of forming very stable immune synapses with tumor cells compared to conventional backbone-based CAR-T cells and can exhibit improved tumor therapeutic efficiency, so they can be useful for immune cell therapy for the treatment of cancer.

Immune synapse-stabilizing chimeric antigen receptor (CAR) T cell

The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.

Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof

Growing community of inventors

Seoul, South Korea

Hyung-Bae Park